Hematologic Malignancy
Mature B-Cell Neoplasm
CI-CAN-00003258Explore in graph →
HematologicNon-malignant1,787 active trials44 approved drugs119 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003258Explore in graph →
Clinical trials
6,664 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00114738 | EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma | completed | Phase 2 | 53 | National Cancer Institute (NCI)NIH | 1 | Oct 10, 2022 | clinicaltrials |
| NCT01775475 | Intravenous Chemotherapy or Oral Chemotherapy in Treating Patients With Previously Untreated Stage III-IV HIV-Associated Non-Hodgkin Lymphoma | completed | Phase 2 | 7 | AIDS Malignancy ConsortiumNETWORK | 2 | Oct 10, 2022 | clinicaltrials |
| NCT01030900 | Phase II Trial of Alemtuzumab (Campath) and Dose-Adjusted EPOCH-Rituximab (DA-EPOCH-R) in Relapsed or Refractory Diffuse Large B-Cell and Hodgkin Lymphomas | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Oct 6, 2022 | clinicaltrials |
| NCT03236792 | Ixazomib In Combination With Cyclophosphamide And Dexamethasone for Newly Diagnosed AL Amyloidosis | completed | Phase 1 / Phase 2 | 28 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Sep 29, 2022 | clinicaltrials |
| NCT01677858 | A Study of Weekly Carfilzomib in Combination With Dexamethasone for Progressive Multiple Myeloma(CHAMPION 1) | completed | Phase 1 / Phase 2 | 116 | AmgenINDUSTRY | 1 | Sep 23, 2022 | clinicaltrials |
| NCT04552743 | MGTA-145 + Plerixafor in the Mobilization of Hematopoietic Stem Cells for Autologous Transplantation in Multiple Myeloma | completed | Phase 2 | 25 | Surbhi Sidana, MDOTHER | 1 | Sep 10, 2022 | clinicaltrials |
| NCT00599495 | Matched Unrelated Donor Stem Cell Transplantation (MUD-SCT) After Dose-reduced Conditioning for Patients With Multiple Myeloma and Relapse After Autologous SCT | completed | Phase 2 | 50 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | Sep 2, 2022 | clinicaltrials |
| NCT00784823 | Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma(Mel-Vel) | completed | Phase 1 / Phase 2 | 32 | Hackensack Meridian HealthOTHER | 1 | Aug 11, 2022 | clinicaltrials |
| NCT01662050 | Phase II Study of Age-Adjusted Rituximab, Bendamustine, Cytarabine as Induction Therapy in Older Patients With MCL(FIL-RBAC500) | completed | Phase 2 | 57 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 9, 2022 | clinicaltrials |
| NCT01119066 | HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies | completed | Phase 2 | 422 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 5, 2022 | clinicaltrials |
| NCT01514344 | Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma(IRIS) | completed | Phase 2 | 20 | Andres J. M. FerreriOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01516593 | Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma(CARMEN) | completed | Phase 2 | 19 | Andres J. M. FerreriOTHER | 1 | Aug 4, 2022 | clinicaltrials |
| NCT02384083 | Filanesib (ARRY-520) in Combination With Pomalidomide and Dexamethasone for Relapsed/Refractory (R/R) Multiple Myeloma (MM) Patients | completed | Phase 1 / Phase 2 | 47 | PETHEMA FoundationOTHER | 1 | Jul 27, 2022 | clinicaltrials |
| NCT02272803 | Phase II Study of Lenalidomide/Dexamethasone With or Without Elotuzumab for Newly Diagnosed MM Patients in Japan | completed | Phase 2 | 82 | Bristol-Myers SquibbINDUSTRY | 1 | Jun 22, 2022 | clinicaltrials |
| NCT02710643 | "MIRO" Molecularly Oriented Immuno-radio-therapy(FIL_MIRO) | completed | Phase 2 | 110 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Jun 21, 2022 | clinicaltrials |
| NCT02977494 | Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment(GMMG-DANTE) | completed | Phase 2 | 22 | Universitätsklinikum Hamburg-EppendorfOTHER | 2 | May 31, 2022 | clinicaltrials |
| NCT03365791 | PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies | completed | Phase 2 | 76 | Novartis PharmaceuticalsINDUSTRY | 1 | May 27, 2022 | clinicaltrials |
| NCT01865617 | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia | completed | Phase 1 / Phase 2 | 204 | Fred Hutchinson Cancer CenterOTHER | 1 | May 25, 2022 | clinicaltrials |
| NCT01261247 | Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma | completed | Phase 2 | 41 | Mayo ClinicOTHER | 1 | May 24, 2022 | clinicaltrials |
| NCT01849783 | Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma | completed | Phase 2 | 41 | Margarida Magalhaes-SilvermanOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT02677324 | Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia | completed | Phase 2 | 33 | Dana-Farber Cancer InstituteOTHER | 1 | May 11, 2022 | clinicaltrials |
| NCT01455051 | Ofatumumab as Part of Reduced Intensity Conditioning (RIC) Regimen for Patients With High Risk Chronic Lymphocytic Leukemia (CLL) Undergoing Allogeneic Hematopoietic Cell Transplantation | completed | Phase 2 | 25 | Grupo Espanol de trasplantes hematopoyeticos y terapia celularOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT01463670 | Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance | completed | Phase 2 | 11 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT01658241 | Panobinostat Biological Correlates Study(VEG VCA1) | completed | Phase 2 | 30 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT03964688 | Effect of Vitamin C in Autologous Stem Cell Transplantations(VICAST) | completed | Phase 2 | 47 | Maastricht University Medical CenterOTHER | 1 | Apr 20, 2022 | clinicaltrials |
| NCT02631577 | A Study Evaluating the Safety and Efficacy of Atezolizumab in Combination With Obinutuzumab Plus Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma | completed | Phase 1 / Phase 2 | 38 | Hoffmann-La RocheINDUSTRY | 2 | Apr 13, 2022 | clinicaltrials |
| NCT01994382 | Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL | completed | Phase 1 / Phase 2 | 260 | Alexion Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 5, 2022 | clinicaltrials |
| NCT03465527 | Pre-phase Treatment Before R-CHOP Chemotherapy in Elderly Patients With Newly Diagnosed DLBCL | completed | Phase 2 | 37 | Kosin University Gospel HospitalOTHER | 1 | Apr 1, 2022 | clinicaltrials |
| NCT03364439 | R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL Patients(FIL_DLCL10) | completed | Phase 2 | 109 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Mar 3, 2022 | clinicaltrials |
| NCT01989598 | Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 25 | National Cancer Institute (NCI)NIH | 1 | Mar 2, 2022 | clinicaltrials |
| NCT04465162 | Radiation Therapy Alone for the Treatment of Stage 1 and 2 Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma | completed | Phase 2 | 75 | M.D. Anderson Cancer CenterOTHER | 1 | Mar 2, 2022 | clinicaltrials |
| NCT03939234 | Peptide Vaccination With PD-L1 and PD-L2 Peptides in Untreated Chronic Lymphatic Leukemia. | completed | Phase 2 | 19 | Lars Møller PedersenOTHER | 1 | Feb 21, 2022 | clinicaltrials |
| NCT03697629 | A Study of an Accelerated Infusion Rate of Daratumumab in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 2 | 40 | Canadian Myeloma Research GroupOTHER | 1 | Feb 15, 2022 | clinicaltrials |
| NCT02077166 | Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma | completed | Phase 1 / Phase 2 | 138 | Pharmacyclics LLC.INDUSTRY | 4 | Feb 4, 2022 | clinicaltrials |
| NCT01496118 | Study of the Combination of Panobinostat and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 80 | SCRI Development Innovations, LLCOTHER | 1 | Feb 2, 2022 | clinicaltrials |
| NCT00477412 | Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 107 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 28, 2022 | clinicaltrials |
| NCT02424851 | Optimising Renal Outcome in Myeloma Renal Failure(OPTIMAL) | completed | Phase 2 | 31 | Oxford University Hospitals NHS TrustOTHER | 1 | Jan 27, 2022 | clinicaltrials |
| NCT04065789 | Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients(KyDaR) | completed | Phase 2 | 41 | Tel-Aviv Sourasky Medical CenterOTHER_GOV | 1 | Jan 27, 2022 | clinicaltrials |
| NCT01125176 | Alternating Thalidomide and Lenalidomide Therapy Plus Rituximab (ThRiL) as Initial Treatment for Patients With CLL(ThRiL) | completed | Phase 2 | 15 | Weill Medical College of Cornell UniversityOTHER | 1 | Jan 21, 2022 | clinicaltrials |
| NCT00924326 | CAR T Cell Receptor Immunotherapy for Patients With B-cell Lymphoma | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Jan 12, 2022 | clinicaltrials |
| NCT02736617 | Obinutuzumab in Combination With Ibrutinib in Treating Patients With Relapsed Mantle Cell Lymphoma | completed | Phase 2 | 10 | OHSU Knight Cancer InstituteOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT01481272 | Ofatumumab With IVAC Salvage Chemotherapy in Diffuse Large B Cell Lymphoma Patients(PLRG8) | completed | Phase 2 | 77 | Polish Lymphoma Research GroupNETWORK | 1 | Dec 27, 2021 | clinicaltrials |
| NCT01962792 | Study of BTK Inhibitor, Ibrutinib in Combination With Carfilzomib in Subjects With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 84 | Pharmacyclics LLC.INDUSTRY | 2 | Dec 21, 2021 | clinicaltrials |
| NCT02983617 | Safety and Efficacy of the Combination of Tirabrutinib and Entospletinib With and Without Obinutuzumab in Adults With Chronic Lymphocytic Leukemia (CLL) | completed | Phase 2 | 36 | Gilead SciencesINDUSTRY | 1 | Dec 21, 2021 | clinicaltrials |
| NCT02639910 | Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi(COSMOS) | completed | Phase 2 | 24 | MorphoSys AGINDUSTRY | 6 | Dec 20, 2021 | clinicaltrials |
| NCT01889186 | A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion | completed | Phase 2 | 158 | AbbVieINDUSTRY | 7 | Dec 16, 2021 | clinicaltrials |
| NCT02086552 | Sonidegib and Lenalidomide After Stem Cell Transplant in Treating Patients With Multiple Myeloma | completed | Phase 2 | 28 | Mayo ClinicOTHER | 1 | Dec 3, 2021 | clinicaltrials |
| NCT01131169 | Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions | completed | Phase 2 | 66 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 2, 2021 | clinicaltrials |
| NCT01793051 | Intervention for Symptom Burden During Maintenance Therapy for Multiple Myeloma | completed | Phase 2 | 88 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 24, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Oct 10, 2022source: clinicaltrials